

# pharma

ISSN 2644-2787

## TECH OUTLOOK

WWW.PHARMATECHOUTLOOK.COM

PHARMA  
MANUFACTURING  
EDITION



*The annual listing of 10 companies that are at the forefront of providing  
Pharma Manufacturing solutions and transforming businesses*



## End-To-End Pharmaceutical Manufacturing Solutions

Since the early 2000s, the U.S. and European pharmaceutical industries have outsourced active pharmaceutical ingredient (API) manufacturing to Asia. This was driven by cheap labor and low taxes, cutting production costs and reducing drug prices. However, COVID-19 and subsequent global supply chain disruptions highlighted the need for in-house API production. To achieve this re-establishment of operations while generating cost-effective drugs and sufficient profitability, pharma manufacturers are adopting modular, continuous production over batch manufacturing.

Leveraging over three decades of experience and industry-leading pharma manufacturing capabilities, Dec Group is ideally positioned to help clients achieve end-to-end drug production in their in-house facilities. The organization acts as a global player offering turnkey solutions and consultancy encompassing molecule handling to the final product packaging process, aiming to uplift productivity, quality, and worker safety.

“We are not an equipment supplier. We provide solutions that enable modular and continuous manufacturing,” says Frederic Dietrich, Managing Director of Dec Group. This helps clients reduce facility footprint by 50 to 60 percent while facilitating flexibility in production volumes and saving costs.


Dec Group initiated operations by introducing an innovative concept for the safe conveying of powder. It developed the powder transfer system (PTS), which redefined powder handling, significantly enhancing containment and process efficiency during the transfer of bulk materials within pharmaceutical manufacturing. This garnered it global acclamation. Since then, as a part of the journey to becoming a comprehensive solutions provider, it acquired Jetpharma for process isolators and micronizing technology, Inno4Life for aseptic fill/finish, Extract



Frederic Dietrich,  
Managing Director

Technology for isolators and contained solutions, and Alconbury Weston for continuous manufacturing, notably flow chemistry solutions. This integration of expertise and technology from the acquisitions and working as a single entity enables it to consistently surpass client expectations.

Its solutions have five primary product divisions that work as a single entity. PTS facilitates enclosed powder handling, mimicking liquid-like safe transfers across manufacturing stages. Its milling technology helps achieve even sub-micron particle sizes, which is vital for superior inhalable drug production. The filling technology is for the aseptic filling of products in vials, syringes, or special packaging and extends to advanced applications like cell and gene therapy and microdosing. The isolator technology handles efficient repackaging of APIs and other materials, while the continuous manufacturing



system connects the dots to ensure reduced production downtime and cost-effective manufacturing.

For superior blending of powders, the company deploys a one-of-a-kind first-order mixing technology dubbed PTS Batchmixer®. Traditional technologies use rotating mixers or agitation tools to blend powders, which degrades product quality. Dec Group’s closed, cleanable, and serviceable mixer has no moving parts and uses circulation to perform the task.



**We are not an equipment supplier. We provide solutions that enable modular and continuous manufacturing**

Addressing its aim to uplift productivity, quality, and operator protection, Dec Group considers certain core values during solution design. It reduces the chances of potential explosions while charging the powders

into reactors containing solvents, maintaining superior safety parameters in the systems. The isolators handle the containment of highly potent and toxic APIs while eliminating hygiene issues like cross-contamination of the powders. When transferring powder across equipment and filling them into tablets and capsules, its closed path PTS technology ensures zero particle damage, no change of powder characteristics, and guarantees a GMP/sterile condition during the packaging of the powder, uplifting drug integrity.

Dec Group’s offerings become a repeated choice for customers because of its comprehensive solutions, which prevent them from approaching multiple vendors for different technologies, reducing cost and lead times. This also benefits them from a compliance standpoint, as the company designs its solutions adhering to the regulatory requirements. If any client wants third-party equipment, it is able to provide that through its collaboration with leading equipment providers.

Dec Group shines as a symbol of comprehensive technological excellence in pharmaceutical manufacturing. Uplifting productivity, quality, and safety of clients’ operations, along with enabling semi and fully continuous manufacturing, it helps clients achieve profitability and competitive advantage in the ever-evolving pharma world.